1. Home
  2. MPB vs DSGN Comparison

MPB vs DSGN Comparison

Compare MPB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mid Penn Bancorp

MPB

Mid Penn Bancorp

HOLD

Current Price

$33.49

Market Cap

827.5M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.32

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPB
DSGN
Founded
1868
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
827.5M
819.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
MPB
DSGN
Price
$33.49
$12.32
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$37.00
$15.25
AVG Volume (30 Days)
116.0K
881.5K
Earning Date
04-21-2026
04-28-2026
Dividend Yield
2.66%
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
N/A
N/A
Revenue This Year
$30.95
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
$91.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.50
$3.33
52 Week High
$35.22
$17.25

Technical Indicators

Market Signals
Indicator
MPB
DSGN
Relative Strength Index (RSI) 53.80 58.30
Support Level $30.82 $11.94
Resistance Level $34.88 $13.54
Average True Range (ATR) 0.83 0.63
MACD 0.07 0.24
Stochastic Oscillator 66.50 88.26

Price Performance

Historical Comparison
MPB
DSGN

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: